<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content

Next Generation Sequencing (NGS) Services

Gain profound molecular insights with our Next Generation Sequencing services as an endpoint for in vivo and ex vivo studies in your preclinical research or clinical trials.

 

Contact us
Learn more
51

Preclinical NGS Services, Now with HT-RNA-Seq  

Champions' experts can help you integrate Whole Exome Sequencing (WES), RNA sequencing (RNAseq), or Whole Transcriptome Sequencing (WTS) into your preclinical studies to discover endless insights. 

  • Tissue processing is available following post-study completion at our US-based facility
  • Fast turnaround times with reliable, high-quality data analysis
  • Data analysis and visualization are delivered through Lumin or analyzed by Champions' dedicated team of bioinformaticians
Contact us

High-Throughput RNA-Seq (HT-RNA-Seq)

We are now offering HT-RNA-Seq, a scale-up transcriptomics assay built for in vivo studies. It delivers the same core biological insight as traditional bulk RNA-Seq, at a meaningfully lower cost per sample, so you can profile significantly more models, treatment arms, and timepoints within the same study budget.

  • Profile substantially more PDX models for the same budget compared to traditional bulk RNA-Seq 
  • Supports large-scale drug response profiling, biomarker discovery, and model stratification across hundreds of samples in a single study
  • Delivers the same gene-expression, differential expression, and pathway-enrichment insight as bulk RNA-Seq; best suited for studies that do not require isoform- or splice-level resolution 
  • Turnaround of approximately 4 to 8 weeks from receipt of your last sample 

In a recent in vivo resistance study, HT-RNA-Seq identified distinct transcriptional signatures separating durable responders from tumors developing acquired resistance, giving researchers a mechanistic, biomarker-level view of resistance as it emerges.

Contact us to scope an HT-RNA-Seq study for your program.

50

Next-Generation Sequencing (NGS) is a high-throughput DNA sequencing technology that enables the rapid and simultaneous sequencing of millions to billions of DNA fragments, revolutionizing genetic analysis compared to traditional Sanger sequencing. At Champions, our experts can help integrate Whole Exome Sequencing (WES), RNA sequencing (RNA-Seq), Digital RNA with Perturbation of Genes Sequencing (DRUG-seq), or Whole Transcriptome Sequencing (WTS) into preclinical studies or clinical trials. By utilizing fluorescently tagged nucleotides, Next-Generation Sequencing services allows for the analysis of a millions of genes and targets at once, enabling the identification of novel and rare variants for in vivo and ex vivo studies using tumor and cells. 


Why choose Champions for your next NGS study?

  • Scientific Oncology Expertise : Champions scientists help you plan each in vivo/ex vivo study with endpoint NGS, to gain meaningful and superior results
  • Quick Turnaround & Execution : Short turn around for analysis post study completion
  • High Quality Results : Multistep quality control results in excellence in each NGS dataset
  • State of the Art NGS Data Visualization : Access to Champions’ Lumin web application to assess your datasets in concert with data assembled from over 12,000+ cancer patients, including thousands of clinical treatment responses not available in any public dataset
 
Champions' Next-Generation Sequencing Services Workflow
NGS workflow

Uncover Deep Molecular Insights using Preclinical Next Generation Sequencing Services

Next Generation Sequencing (NGS) can be utilized as an endpoint for in vivo and ex vivo studies to provide a deeper understanding of the model to better stratify responders versus non-responders and to discover novel biomarkers to guide patient selection.

In particular, DRUG-seq can be used to study an agent's effect on the transcriptome and investigate mechanisms of action and profiles of drug response and resistance, using limited starting material.

As oncology experts, our team has deep scientific competencies to not only aid in the planning of your upcoming in vivo or ex vivo study, but to recommend NGS endpoint analyses that can help you discover powerful insights with your therapeutic candidate from our highly characterized tumor bank.

Contact us
49
 
AACR 2026 Poster #6415: Scalable chem-seq and functional-seq platforms for profiling chemical and genetic perturbations in patient-derived organoids

Large-scale functional drug screening has been limited by low throughput reliance on simple 2D systems and a lack of high-resolution mechanistic readouts. To address these challenges, we implemented Chem-Seq and Functional-Seq, scalable transcriptomic profiling platforms that enable high-content screening of both chemical and genetic perturbations in clinically relevant cancer models.
 
6415-thumb

 

Ready to start working with Champions Oncology? 
Frequently Asked Questions
What is HT-RNA-Seq and how is it different from bulk RNA-Seq?

HT-RNA-Seq is Champions' scale-up transcriptomics assay, built specifically for in vivo studies that need to cover more ground within a fixed budget. It captures the same core biological insight as traditional bulk RNA-Seq (gene expression, differential expression, and pathway enrichment) using a 384-well workflow that allows samples to be pooled and processed at much greater scale. The trade-off is coverage depth: HT-RNA-Seq reads the 3' end of transcripts rather than sequencing full-length, so it is not the right choice for isoform or splice-variant analysis. For the large majority of studies focused on gene-level expression changes rather than splicing detail, that trade-off has no practical impact on the results. Turnaround is typically 4 to 8 weeks from receipt of your last sample. 

What NGS services does Champions Oncology offer for preclinical studies?

Champions offers a full suite of next-generation sequencing services for preclinical oncology research, including Whole Exome Sequencing (WES), RNA sequencing (RNA-Seq), Whole Transcriptome Sequencing (WTS), and our new high-throughput HT-RNA-Seq platform for studies that need to profile more models, arms, or timepoints within the same budget. Data analysis and visualization are delivered through Lumin or by Champions' dedicated team of bioinformaticians, so you can go from raw sequencing data to actionable biomarker and mechanism-of-action insights without building that capability in-house. 

Get in touch

Fill out the form to learn more about using Champions’ NGS Services as endpoints in your preclinical studies.